预防性 HPV 疫苗预防癌症。
Prevention of cancer by prophylactic human papillomavirus vaccines.
机构信息
Department of Pathology, The Johns Hopkins University, Baltimore, MD 21231, USA.
出版信息
Curr Opin Immunol. 2011 Apr;23(2):244-51. doi: 10.1016/j.coi.2010.11.009. Epub 2010 Dec 23.
Abstract
Oncogenic human papillomaviruses (HPVs) are exclusively mucosal pathogens that are noncytopathic and the basal epithelial cells harboring and maintaining an infection do not produce either capsid antigen or virus. The efficacy of the licensed L1 virus-like particle (VLP) vaccines has encouraged development of several second generation vaccines aimed at expanding the coverage to all oncogenic HPV types and reducing barriers to global implementation. Currently there is no defined immune correlate of protection that can be used to determine if an individual patient is protected and for the evaluation of these second generation vaccines. Surprisingly, passive transfer of neutralizing serum antibody is protective in animal models. Recent studies suggest how neutralizing antibody mediates immunity against mucosal HPV and the possible impact of memory B cells.
摘要
致癌型人乳头瘤病毒（HPV）是专性黏膜病原体，无细胞病变作用，且感染的基底上皮细胞不产生衣壳抗原或病毒。已获许可的 L1 病毒样颗粒（VLP）疫苗的有效性促使人们开发了几种第二代疫苗，旨在扩大覆盖范围，涵盖所有致癌型 HPV 类型，并减少全球实施的障碍。目前尚无明确的免疫保护相关因素可用于确定个体患者是否受到保护，也无法用于评估这些第二代疫苗。令人惊讶的是，中和血清抗体的被动转移在动物模型中具有保护作用。最近的研究表明中和抗体如何介导针对黏膜 HPV 的免疫以及记忆 B 细胞的可能影响。
相似文献
1
Prevention of cancer by prophylactic human papillomavirus vaccines.预防性 HPV 疫苗预防癌症。
Curr Opin Immunol. 2011 Apr;23(2):244-51. doi: 10.1016/j.coi.2010.11.009. Epub 2010 Dec 23.
2
Developments in L2-based human papillomavirus (HPV) vaccines.基于第二代的人乳头瘤病毒（HPV）疫苗的进展。
Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23.
3
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.由L1/L2嵌合病毒样颗粒组成的人乳头瘤病毒疫苗在临床前模型中诱导产生广泛的交叉保护作用。
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
4
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.RG1-VLP 疫苗接种对预防生殖器和皮肤人乳头瘤病毒感染的疗效。
J Invest Dermatol. 2013 Dec;133(12):2706-2713. doi: 10.1038/jid.2013.253. Epub 2013 May 10.
5
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.次要衣壳蛋白L2多表位诱导针对致癌性和黏膜型人乳头瘤病毒的广泛保护。
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01930-17. Print 2018 Feb 15.
6
In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.高危型人乳头瘤病毒 L1 和 L2 保守序列的计算机模拟/体内分析，用于开发跨亚型预防性疫苗。
Sci Rep. 2019 Oct 23;9(1):15225. doi: 10.1038/s41598-019-51679-8.
7
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.一种嵌合的18L1-45RG1病毒样颗粒疫苗可对致癌性α-7型人乳头瘤病毒各型提供交叉保护。
PLoS One. 2015 Mar 19;10(3):e0120152. doi: 10.1371/journal.pone.0120152. eCollection 2015.
8
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.RG2-VLP：一种旨在广泛预防导致人类癌症的肛门生殖器和皮肤人乳头瘤病毒的疫苗。
J Virol. 2022 Jul 13;96(13):e0056622. doi: 10.1128/jvi.00566-22. Epub 2022 Jun 15.
9
Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.口服噬菌体 MS2-L2 VLP 免疫可预防与头颈部癌症和宫颈癌相关的多种 HPV 型别的口腔和生殖器感染。
Antiviral Res. 2019 Jun;166:56-65. doi: 10.1016/j.antiviral.2019.03.012. Epub 2019 Mar 26.
10
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?基于病毒样颗粒的抗人乳头瘤病毒疫苗：我们如今进展如何？
Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018.
引用本文的文献
1
HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.通过首次尿潴留收集的女性生殖道分泌物中的 HPV 特异性抗体保留其中和能力。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2330168. doi: 10.1080/21645515.2024.2330168. Epub 2024 Apr 3.
2
The transmembrane replacement H7N9-VLP vaccine displays high levels of protection in mice.跨膜替代H7N9病毒样颗粒疫苗在小鼠中显示出高水平的保护作用。
Front Microbiol. 2022 Oct 6;13:1003714. doi: 10.3389/fmicb.2022.1003714. eCollection 2022.
3
Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation.乳头瘤病毒主要衣壳蛋白的异构体在阻断病毒传播和肿瘤形成的能力上存在差异。
Front Immunol. 2022 Mar 14;13:811094. doi: 10.3389/fimmu.2022.811094. eCollection 2022.
4
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine.接种疫苗的年龄对人乳头瘤病毒疫苗体液免疫反应的影响。
NPJ Vaccines. 2022 Mar 15;7(1):37. doi: 10.1038/s41541-022-00458-0.
5
Expression of different L1 isoforms of papillomavirus as mechanism to circumvent adaptive immunity.不同 HPV 长型异构体的表达作为规避适应性免疫的机制。
Elife. 2020 Aug 4;9:e57626. doi: 10.7554/eLife.57626.
6
A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects.单剂量人乳头瘤病毒疫苗可改善既往感染者的B细胞记忆。
EBioMedicine. 2016 Aug;10:55-64. doi: 10.1016/j.ebiom.2016.06.042. Epub 2016 Jun 29.
7
A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo.表达人乳头瘤病毒16型L1的活载体在体内产生佐剂诱导的抗体反应。
Iran J Cancer Prev. 2015 Dec;8(6):e3991. doi: 10.17795/ijcp-3991. Epub 2015 Dec 23.
8
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.表达人乳头瘤病毒16型E6和E7的减毒重组甲型流感病毒作为一种新型治疗性疫苗方法
PLoS One. 2015 Sep 18;10(9):e0138722. doi: 10.1371/journal.pone.0138722. eCollection 2015.
9
A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.一种基于嵌合型EBV gp350/220的病毒样颗粒（VLP）复制了病毒粒子的B细胞附着机制，并在小鼠体内引发持久的中和抗体。
J Transl Med. 2015 Feb 6;13:50. doi: 10.1186/s12967-015-0415-2.
10
Down-regulation of Frizzled-7 expression inhibits migration, invasion, and epithelial-mesenchymal transition of cervical cancer cell lines.卷曲蛋白-7（Frizzled-7）表达下调可抑制宫颈癌细胞系的迁移、侵袭及上皮-间质转化。
Med Oncol. 2015 Apr;32(4):102. doi: 10.1007/s12032-015-0552-8. Epub 2015 Mar 5.
本文引用的文献
1
In vivo mechanisms of vaccine-induced protection against HPV infection.HPV 感染疫苗诱导保护的体内机制。
Cell Host Microbe. 2010 Sep 16;8(3):260-70. doi: 10.1016/j.chom.2010.08.003.
2
Papillomavirus infection requires gamma secretase.人乳头瘤病毒感染需要γ分泌酶。
J Virol. 2010 Oct;84(20):10661-70. doi: 10.1128/JVI.01081-10. Epub 2010 Aug 11.
3
Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.描述未加佐剂 HPV16 L1 VLP 疫苗接种女性的 HPV 特异性记忆 B 细胞和系统抗体应答。
Vaccine. 2010 Jul 26;28(33):5407-13. doi: 10.1016/j.vaccine.2010.06.018. Epub 2010 Jun 17.
4
Measuring serum antibody to human papillomavirus following infection or vaccination.检测 HPV 感染或接种疫苗后的血清抗体。
Gynecol Oncol. 2010 Jun;118(1 Suppl):S8-11. doi: 10.1016/j.ygyno.2010.04.003.
5
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.接种多聚体 L2 融合蛋白和 L1 VLP 或衣壳小体以扩大对 HPV 感染的保护。
Vaccine. 2010 Jun 17;28(28):4478-86. doi: 10.1016/j.vaccine.2010.04.039. Epub 2010 Apr 29.
6
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments.基于 189 种 HPV 型别对乳头瘤病毒（PVs）的分类以及分类学修订建议。
Virology. 2010 May 25;401(1):70-9. doi: 10.1016/j.virol.2010.02.002. Epub 2010 Mar 5.
7
Role of L2 cysteines in papillomavirus infection and neutralization.L2 半胱氨酸在乳头瘤病毒感染和中和中的作用。
Virol J. 2009 Oct 27;6:176. doi: 10.1186/1743-422X-6-176.
8
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.嵌合L1-L2病毒样颗粒作为潜在的广谱人乳头瘤病毒疫苗。
J Virol. 2009 Oct;83(19):10085-95. doi: 10.1128/JVI.01088-09. Epub 2009 Jul 29.
9
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.串联多类型L2融合蛋白作为候选预防性全人乳头瘤病毒疫苗
J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.
10
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.研发针对次要衣壳抗原L2的疫苗以预防乳头瘤病毒感染。
Immunol Cell Biol. 2009 May-Jun;87(4):287-99. doi: 10.1038/icb.2009.13.
Zotero 插件